Timothy J Voorhees
Ohio State University Comprehensive Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Timothy J Voorhees as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 06:41 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT06741072 · BZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ TransplantsOhio State University Comprehensive Cancer Center · recruiting · Chronic Kidney Disease, Stage 4, Chronic Kidney Disease, Stage 5, EBV-Related Lymphoproliferative Disorder · principal investigator
- Ph1NCT06672705 · Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative DisordersTimothy Voorhees · recruiting · Diffuse Large B-Cell Lymphoma Post-Transplant Lymphoproliferative Disorder, EBV-Related Post-Transplant Lymphoproliferative Disorder, Recurrent Monomorphic Post-Transplant Lymphoproliferative Disorder · principal investigator
- Ph2NCT05786040 · Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative DisorderTimothy Voorhees · recruiting · Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder, Polymorphic Post-Transplant Lymphoproliferative Disorder · principal investigator
- Ph1NCT05665725 · Siltuximab for the Prevention of CAR T Cell Related Cytokine Release Syndrome in Patients With CD19 Positive Non-Hodgkin LymphomaTimothy Voorhees · completed · Non-Hodgkin Lymphoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 06:41 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Epstein-Barr Virus positive post-transplant lymphoproliferative disorders: identifying viral and host variables to predict risk and therapeutic responsesR01CA308586 · NCI · OHIO STATE UNIVERSITY · fiscal years 2026 · $366,965 awarded in 2026Grant number is on one of their registry trials
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 06:41 UTC. The ranking covers the 200 most relevant of 2 PubMed records, and a shared surname and initials can bring in a namesake. All 2 on PubMed